Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Insulin Formulation in Type 2 Diabetes Mellitus
NCT06473662Phase 2Completed
- Start
- Oct 2018
- Primary completion
- Jul 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of regular human insulin in type 2 diabetes mellitus (T2DM) (3 arms). Primary endpoint: Change in HbA1c at 12 weeks. Started Oct 2018; status: completed.
02
Drugs
regular human insulin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06473662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06473662.